Formulation development of chewable albendazole tablets with improved dissolution rate (Record no. 19237)

MARC details
000 -LEADER
fixed length control field 02900nam a22002897a 4500
003 - CONTROL NUMBER IDENTIFIER
control field OSt
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20240305193719.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 221102b |||||||| |||| 00| 0 eng d
028 ## - PUBLISHER OR DISTRIBUTOR NUMBER
Source Phone: +255 28 298 3384
Source Fax: +255 28 298 3386
Source Email: vc@bugando.ac.tz
Source Website: www.bugando.ac.tz
040 ## - CATALOGING SOURCE
Transcribing agency DLC
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title English
100 ## - MAIN ENTRY--PERSONAL NAME
Personal name Emmanuel Kimaro
9 (RLIN) 26657
245 ## - TITLE STATEMENT
Title Formulation development of chewable albendazole tablets with improved dissolution rate
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Place of publication, distribution, etc. Mwanza:
Name of publisher, distributor, etc. Elsevier &
-- Tanzania Catholic University of Health and Allied Sciences [CUHAS – Bugando]
Date of publication, distribution, etc. 2019/12/1
300 ## - PHYSICAL DESCRIPTION
Extent Pages e02911
490 ## - SERIES STATEMENT
Volume/sequential designation Journal Heliyon Volume 5 Issue 12
520 ## - SUMMARY, ETC.
Summary, etc. Abstract<br/><br/>Background<br/><br/>Albendazole is an orally administered broad-spectrum anthelmintic. Currently it is mostly used in the treatment of soil transmitted helminthes, hydatidosis and neurocysticercosis caused Taenia solium.<br/><br/>Aim of the study. To develop and optimize a formulation of chewable albendazole tablet with improved dissolution rate.<br/><br/>Methodology<br/><br/>This study was specifically focused on formulation development which passes compatibility studies and optimization of the developed formulation. The formulations were evaluated on assay, dissolution, friability, hardness, weight variation, disintegration and similarity in comparison with the reference product on the market. Analysis was required to be undertaken by High performance thin layer chromatography (HPTLC) analytical methods. Design of Expert version 7 software was used for selection or making scientific decisions in selecting the best composition of the best formulation.<br/><br/>Results<br/><br/>Five formulations out of ten (F-6, F-7, F-8, F-9 and F10) had all parameters in acceptable range. On optimization, one formulation with independent variables, Sodium Laury Sulphate (SLS) 1.911%, polyvinyl pyrrolidone (PVP-K30) 3.128%, and Sodium Cross carmellose (CCM) 4.95% was selected out of ten predictions made with Design expert version 7.0. It was found that assay of the best formulation is 99.23% which was within the in-house assay specification 95–105%. Dissolution single point in 30 min was found to be 91.5% disintegration between 2-5 min and friability 0.45%.The optimized formulation was tested and found to be within the acceptable limits. The formulation was comparable to the reference product on the market with similarity factor (f2) 62 and difference factor (f1) of 6 at pH1.2.<br/><br/>Conclusion<br/><br/>A new generic albendazole tablet with improved dissolution rate was formulated, developed and optimized by using a wet granulation method.
700 ## - ADDED ENTRY--PERSONAL NAME
9 (RLIN) 44994
9 (RLIN) 44995
9 (RLIN) 44996
9 (RLIN) 44997
856 ## - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1016/j.heliyon.2019.e02911">https://doi.org/10.1016/j.heliyon.2019.e02911</a>
942 ## - ADDED ENTRY ELEMENTS (KOHA)
Source of classification or shelving scheme ddc
Koha item type RESEARCH ARTICLES
Holdings
Withdrawn status Lost status Source of classification or shelving scheme Damaged status Not for loan Collection Home library Current library Shelving location Date acquired Total checkouts Barcode Date last seen Price effective from Koha item type
            MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO   11/02/2022   RA0438 11/02/2022 11/02/2022 RESEARCH ARTICLES
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024